iRGD-modified exosomes-delivered BCL6 siRNA inhibit the progression of diffuse large B-cell lymphoma

Clinical applications of siRNA therapeutics have been limited by the immunogenicity of the siRNA and low efficiency of siRNA delivery to target cells. Recently, evidence have shown that exosomes, endogenous nano-vesicles, can deliver siRNA to the tumor tissues in mice. Here, to reduce immunogenicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qinhua, Dai, Guanrong, Wu, Yi, Zhang, Mingxia, Yang, Mingya, Wang, Xiaonan, Song, Mingyue, Li, Xiaodan, Xia, Ruixiang, Wu, Zhengsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378967/
https://www.ncbi.nlm.nih.gov/pubmed/35982974
http://dx.doi.org/10.3389/fonc.2022.822805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378967/
https://www.ncbi.nlm.nih.gov/pubmed/35982974
http://dx.doi.org/10.3389/fonc.2022.822805

Ejemplares similares